Who's Acquiring Supplement Brands? Acquirers and Multiples 2026

Every supplement founder I work with at $5M to $50M has seen the same headlines. PepsiCo paid nearly two billion dollars for Poppi. Nestle paid almost six billion for Bountiful. Then they look at their own brand, with its loyal subscriber base and decent margins, and ask the only question that matters: what would someone actually pay for this, and what makes that number go up?

Here is the honest answer. Supplements and functional wellness trade at a premium to most consumer categories, and the reasons are gross margin and recurring revenue. But the headline deals are the top of the distribution, not the middle. Below is who is buying, what they are paying, and the specific levers that separate a 2x exit from a 4x one.

Who is actually buying supplement brands

The 2025 and 2026 buyer pool splits into three camps.

Strategics are writing the biggest checks: Nestle Health Science, PepsiCo, Danone, Simply Good Foods, USANA, Glanbia and BellRing. They buy for portfolio gaps, growth they cannot build organically, and access to a younger or more health-focused consumer. These deals set the headline multiples because a strategic can underwrite distribution and manufacturing synergies a financial buyer cannot.

Private equity and platform aggregators are active at the smaller end, typically rolling up sub-scale brands or backing a founder for a second act. Nutrabolt taking the rest of Bloom Nutrition is a good example. They underwrite to EBITDA and cash flow, which usually means a lower revenue multiple than a strategic will pay for the same brand, because they are not buying distribution synergy.

The legacy nutrition and CPG majors sit inside the strategic camp but behave differently. They want proven, profitable, scaled assets that survive being run through a giant P&L, not momentum stories that need founder magic. It is worth noting the cycle can reverse: Nestle signaled in 2025 it was weighing a sale of parts of its supplement portfolio, the same Bountiful brands it bought for $5.75 billion in 2021.

For a private operator, the camp that buys you determines your multiple. A strategic chasing your growth and your subscriber data will pay more than a PE firm modeling your free cash flow.

What multiples supplement brands command

Across 2024 to YTD 2025, vitamins and supplements averaged about 10.7x EV/EBITDA, according to Capstone Partners (Capstone Partners), above the 9.7x average for broader consumer. That is a real premium, but EBITDA multiples only apply to profitable, scaled brands. For the growth-stage DTC brands most founders run, deals get quoted on revenue, and there the spread is wide.

The named deals tell the story:

• PepsiCo / Poppi (2025): about $1.95B (PepsiCo) on an estimated ~$590M of revenue, an implied ~3.3x. PepsiCo does not disclose Poppi's standalone revenue, so the multiple is an estimate (Eightx analysis). A strategic paying up for a fast-growing functional-soda brand that fills a better-for-you gap PepsiCo could not build fast enough.
• Danone / Huel (2026): roughly 1 billion euros ($1.2B) on about 250 million pounds of 2025 revenue, around 3.4x (NutraIngredients). A premium for a category-defining meal-replacement and nutrition brand with a loyal subscriber base.
• Nestle Health Science / The Bountiful Company (2021): $5.75B on about $1.87B of trailing sales, roughly 3.1x net sales (16.8x EBITDA), per Nestle's disclosure (Nestle). The deal that defined the modern strategic appetite for scaled supplement portfolios.
• Simply Good Foods / OWYN (2024): $280M on about $120M of expected 2024 net sales, an implied 2.3x revenue, or 13.3x adjusted EBITDA including run-rate synergies per the company's deal materials (Simply Good 8-K). A clean tuck-in of a plant-based protein brand into a bigger nutrition platform.
• USANA / Hiya Health (2024): $205M for a 78.8% controlling stake on about $103M of LTM net sales through September 2024, roughly 2.0x revenue, with a put/call structure on the rest (USANA 8-K).

The pattern M&A advisers describe for 2026 holds here: scaled, profitable, subscription-heavy supplement assets trade roughly 3x to 4x revenue, while sub-scale or commoditized brands sit closer to 1x to 2x (Eightx analysis, synthesized from the deal comps above). Nutrabolt buying the remaining stake in Bloom Nutrition (Nutrabolt) at an estimated ~0.6x EV/revenue shows the floor for a brand without a defensible margin and growth story.

What actually drives the multiple up

A revenue multiple is not magic. It is a proxy for three things an acquirer can underwrite.

Gross margin is the foundation. Indie supplement brands run 55% to 70% gross margin, tracking close to beauty and well above packaged food at 30% to 49%, per our average gross margin by CPG category. Subscription supplement brands that capture full MSRP at low ingredient cost on capsules, powders and gummies can run even higher before fulfillment. That gross profit is what funds the marketing spend supplements need, which is why acquirers pay more per dollar of revenue here than in food. A brand at 55% gross margin and one at 70% are not in the same conversation, even at the same revenue.

Recurring revenue and low churn move the number. Supplements are the rare DTC category where the product is consumed on a predictable cycle, so subscription is the dominant model. A buyer pays for a revenue base that renews itself. A brand with 60% of revenue on subscription and low churn is worth materially more than the same topline built on one-time, discount-driven orders. The economics of that subscriber base are the whole game, which we break down in supplements subscription economics.

Compliance and operating quality determine whether the multiple holds. Supplements carry FDA structure-function rules and FTC substantiation requirements that beauty and food do not face the same way. An acquirer prices regulatory risk hard: a brand with clean claims, documented testing and no warning-letter history gets the high end. The same polarization shows up across DTC generally. Our public DTC margin leaderboard found a thin median operating margin and a third of public DTC brands losing money. Supplements' gross-margin advantage is real, but it does not exempt a brand from the discipline that separates a premium exit from a fire sale. The category map of where the white space sits is in our CPG white space map, and the broader nutrition comps are in our food and beverage CPG public benchmarks.

What to do about it

If you are building toward an exit or a raise, here is the work, in order.

1. Get gross margin above 60% and prove it is durable. That usually means moving from contract-manufacturer markups toward direct ingredient sourcing and better formulation cost control. It is a 12 to 18 month project and the single highest-leverage move at your revenue band.
2. Make the subscription base bulletproof. Show retention curves, churn by cohort, and contribution margin after CAC on subscribers versus one-time buyers. Acquirers pay for recurring revenue they can model, and a clean payback story is the proof, covered in supplement CAC payback benchmarks.
3. Lock down FDA and FTC compliance before diligence. Have your claims substantiation, testing records and label compliance organized. A single unresolved regulatory issue can knock a full turn off your multiple or kill the deal.
4. Produce 12 plus months of clean contribution-margin data by channel. Acquirers pay for proof, not narrative. Show CM after CAC by channel so a buyer can see which growth is profitable.
5. Get your books diligence-ready early. The deal-killer is not a low number, it is a surprise in the data room. Clean, accrual-based books that tie out save you points on the multiple. The full pre-sale checklist is in our guide to DTC brand exit financial readiness.

This is exactly the kind of pre-deal preparation our fractional CFO for supplements brands team runs: tightening the margin story, proving the subscription base, and making sure the number an acquirer arrives at reflects the business you actually built.

Frequently Asked Questions